HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Consolidated Financial Statements Continued 14.
Intangible assets ProductMarketing Customer related rights and Goodwill relationships intangibles Trade names others Software Total $m $m $m $m $m $m $m Cost Balance at 1 January 2014 279 78 118 11 17 30 533 Additions 19 1 5 25 Acquisition of business 51 123 174 Translation adjustments 15 3 4 1 1 1 25 Balance at 1 January 2015 315 75 256 10 17 34 707 Additions 35 2 19 56 Remeasurement note 43 8 8 Translation adjustments 14 6 4 1 1 1 27 Balance at 31 December 2015 293 69 287 9 18 52 728 Amortisation Balance at 1 January 2014 1 29 30 2 8 16 86 Charge for the year 5 8 1 4 18 Impairment 5 5 Translation adjustments 1 1 1 1 4 Balance at 1 January 2015 1 33 42 2 8 19 105 Charge for the year 5 10 1 4 20 Impairment 2 2 Translation adjustments 3 2 1 6 Balance at 31 December 2015 1 35 52 2 9 22 121 Carrying amount At 31 December 2015 292 34 235 7 9 30 607 At 31 December 2014 314 42 214 8 9 15 602 The current year additions include licences and new products under development.
An adjustment of $8 million was made to the provisional goodwill recognised on the acquisition of Bedford as a result of the adjustment to property, plant and equipment, inventory and deferred taxes made prior to the end of the measurement period on 15 July 2015 note 43.
As at 31 December 2015, the Group had Intangible assets under development amounting to $156 million 2014: $154 million which are not subject to amortisation until ready for use.
Goodwill acquired in a business combination is allocated, at acquisition, to the cash generating units CGUs that are expected to benefit from that business combination.
The carrying amount of goodwill has been allocated as follows: As at 31 December 2015 2014 $m $m Branded 187 199 Injectables: 75 83 MSI 32 32 Bedford 43 51 Oncology 30 32 Total 292 314 156 156 FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 14.
Intangible assets continued ProductMarketing The Group tests goodwill annually for impairment or more frequently if there are indications that goodwill may be impaired.
Customer related rights and Goodwill relationships intangibles Trade names others Software Total Details related to the discounted cash flow models used in the impairment tests of CGUs are as follows: $m $m $m $m $m $m $m Valuation basis Higher of fair value less costs of disposal and value in use Cost Key assumptions Sales growth rates Balance at 1 January 2014 279 78 118 11 17 30 533 Additions 19 1 5 25 Profit margins Terminal growth rate Acquisition of business 51 123 174 Translation adjustments 15 3 4 1 1 1 25 Discount rate Balance at 1 January 2015 315 75 256 10 17 34 707 Determination of assumptions Growth rates are internal forecasts based on both internal and external market information.
Additions 35 2 19 56 Margins reflect past experience, adjusted for expected changes.
Remeasurement note 43 8 8 Terminal growth rates based on managements estimate of future long-term average growth rates.
Translation adjustments 14 6 4 1 1 1 27 Discount rates based on Group WACC, adjusted where appropriate.
Balance at 31 December 2015 293 69 287 9 18 52 728 Period of specific Amortisation projected cash flows 5 years Balance at 1 January 2014 1 29 30 2 8 16 86 Terminal growth rate Terminal growth Pre-tax discount Charge for the year 5 8 1 4 18 and discount rate rate perpetuity rate Impairment 5 5 Branded 2% 14% Translation adjustments 1 1 1 1 4 MSI 2% 11% Balance at 1 January 2015 1 33 42 2 8 19 105 Bedford 2% 11% Charge for the year 5 10 1 4 20 Oncology 2% 11% Impairment 2 2 Branded discount rate is blended according to the operating profits of the associated market country included in the cash flows of the CGU.
Translation adjustments 3 2 1 6 Balance at 31 December 2015 1 35 52 2 9 22 121 The Group has conducted a sensitivity analysis on the impairment test of each CGUs carrying value.
In each case the valuations indicate Carrying amount sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in an impairment of the related goodwill.
At 31 December 2015 292 34 235 7 9 30 607 Whilst there is some uncertainty regarding the short-term impact of the political events in MENA, the Group does not consider that the likelihood of impairment losses in the long-term has increased.
At 31 December 2014 314 42 214 8 9 15 602 The current year additions include licences and new products under development.
The carrying amount of goodwill has been allocated as follows: As at 31 December 2015 2014 $m $m Branded 187 199 Injectables: 75 83 MSI 32 32 Bedford 43 51 Oncology 30 32 Total 292 314 156 157 157 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Consolidated Financial Statements Continued 14.
Intangible assets continued Other intangible assets Amortisation of all intangible assets with finite useful lives is charged on a straight-line basis.
Customer relationships: Customer relationships represent the value attributed to the existing direct customers that the Company acquired on the acquisition of subsidiaries.
The customer relationships have an average estimated useful life of 15 years 2014: 15 years.
Product related intangibles: Product related intangibles include four types: a.
Product files and under-licenced products: $6 million 2014: $20 million of the product files and under-licence products intangibles are assessed as having indefinite useful lives due to the expected longevity of the products.
b. Under-licence agreements: The estimated useful life of under-licence agreements varies from five to eleven years 2014: five to eleven years.
c. Product dossiers: Product dossiers have an average estimated useful life of 15 years 2014: 15 years.
d. In process product files: Mainly represent files acquired from Bedford that are in the process of being transferred to our manufacturing facilities.
Trade name: Trade names were mainly recognised on the acquisition of Hikma Germany GmbH Germany, Arab Pharmaceutical Manufacturing Company, Promopharm, and Ibn Al Baytar.
The trade name recognised on the acquisition of Hikma Germany GmbH Germany is expected to have an indefinite economic useful life due to its expected longevity.
The carrying value of Hikma Germany GmbH Germany trade name is $5 million 2014: $5 million.
The trade names recognised on the acquisition of the other subsidiaries have useful lives that vary from three to twenty years.
Marketing rights: Marketing rights are amortised over their useful lives commencing in the year in which the rights are ready for use.
The estimated useful life of marketing rights varies from five to ten years.
b. In-process R&D: In-process R&D represents mainly the pipeline of products under development that were recognised on the acquisition of Arab Pharmaceutical Manufacturing Company and Hikma Pharma SAEEgypt.
The in-process R&D has an average estimated useful life of 15 years 2014: 15 years.
c. Other acquisition related: This mainly represents intangible assets recognised on the acquisition of Thymoorgan, which relate to its specialist manufacturing capabilities.
The estimated useful life varies from 10 years to an indefinite useful life.
The carrying value of assets with indefinite lives is $1 million 2014: $1 million.
Software: Software intangibles mainly represent the Enterprise Resource Planning solutions that are being implemented in different operations across the Group.
The software has an average estimated useful life of five years.
As at 31 December 2015, the Group had entered into contractual commitments for the acquisition of intangible assets of $49 million 2014: $45 million.
